Navigation Links
Study using stem cells to improve organ transplantation to receive $12 million
Date:11/7/2013

CHICAGO An innovative Northwestern Medicine research program investigating if stem cells may be the key to allowing organ transplant patients to stop taking immunosuppressive drugs has received $12 million in research funding. The grant will allow researchers to finish Phase II of the clinical trials and begin Phase III. Northwestern began the study's clinical trial in early 2009 as part of a partnership with the University of Louisville, which engineers the specialized stem cells used in each transplant procedure.

"During our clinical trials, we have been able to take the novel stem cell technology that the University of Louisville pioneered from the bench to the bedside," said Joseph Leventhal, MD PhD, director of kidney and pancreas transplantation at Northwestern Memorial Hospital, and professor of Surgery at Northwestern University Feinberg School of Medicine. "The results of our clinical trial were a catalyst for Novartis' long-term investment in this new cellular based therapy for solid organ transplantation."

The clinical trial uses specially engineered stem cells from kidney donors to make the organ recipient's immune system recognize the new kidney as its own. In mainstream transplant procedures, a recipient faces the danger of their immune system treating a newly transplanted organ as a foreign body that should be removed, causing it to attack and try to kill the new organ. To prevent a recipient's immune system from attacking their new organ, doctors must currently prescribe toxic anti-rejection medicines to weaken the immune system and keep it at bay.

In March of 2012, Leventhal and his colleagues published the study's initial clinical results from eight participants in Science Translational Medicine. The article outlined that of the study's eight participants, five were able to successfully stop taking all anti-rejection medicines in just one year after they received a new kidney, and two required only low-doses of anti-rejection medicine to be maintained instead of a normal regimen. The final patient suffered an unrelated illness that required another kidney transplant to be performed.

"Northwestern's Comprehensive Transplant Center has demonstrated for the first time in the history of organ transplantation that we can safely achieve durable transplantation tolerance in mismatched and unrelated donor/recipient combinations," said Leventhal. "I am very excited to be able to continue this groundbreaking translational research."

The first subjects to participate in the research study underwent surgery on February 26, 2009. To date, more than 20 patients have been enrolled and have received new kidneys as part of the clinical trial, the majority of which have been successfully taken off of all anti-rejection medicines. In order to qualify, the donor and recipient pairs must be blood-type compatible and have a negative cross-match, which means that testing has been done to confirm the recipient does not have antibodies in the blood that would cause rejection of the kidney.

The grant is a result of a license and research collaboration agreement between Regenerex LLC and Novartis to provide access to the novel technology developed by the University of Louisville's Institute for Cellular Therapeutics. Leventhal does not receive financial incentives or payment from Novartis or Regenerex LLC.


'/>"/>

Contact: Bret Coons
bcoons@nmh.org
312-926-2955
Northwestern Memorial Hospital
Source:Eurekalert

Related medicine news :

1. FDA awards $2.25M grant to study immunosuppresive drug in high-risk patients
2. Study finds that Americans want doctors guidance on genetic test results
3. New study assesses injuries seen in the emergency department to children of teenage parents
4. Study Finds Infants Under 6 Months Too Young for Flu Shot at High Risk to Influenza Fatalities- UV Technologies Makers of UV-Aid, Develop New Flu Prevention Alternative
5. Independent Naturopathic Clinic Receives Groundbreaking Research Grant: Partners with Global Pharmaceutical Company to Study Relief of Cancer Drug Side Effects
6. 20 percent of nations GME funds go to New York while 29 states get less than 1 percent, study says
7. Physician shortage could be cut by new primary care models, study finds
8. Study: Access to health care increases prescription opioid availability and associated abuse
9. Study: Higher rates of diabetes, hypertension, heart disease and stroke found in food desert
10. U-M study: Smarter blood pressure guidelines could prevent many more heart attacks and strokes
11. Study looks at safety, effectiveness of generics for treating depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global data and ... Premier Research, a leading clinical development service provider, has selected ERT’s Trial Oversight ... due in part to an array of circumstances including the use of multiple ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... partnership with the Rhode Island Consortium for Autism Research and Treatment (RI-CART) and ... children with autism spectrum disorder (ASD) to see films in an environment that ...
(Date:2/23/2017)... ... 23, 2017 , ... Top cosmetic and periodontal dentist Dr. Mahnaz Rashti ... new Indiegogo campaign . Individuals are now able to contribute to the local ... either as a participating patient or through an Indiegogo donation. The entirety of proceeds ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thomas Vas-Don suffered from severe injury ... author was able to successfully recover. In “ Origin & Insertion Charts for Massage ... on the principals of massage, anatomy , trigger points and referral pain ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... and athletics. It’s enough to overwork even the sharpest brain. , Power On, ... peak healthy activity without over clocking the brain. Each capsule contains Cognizin® Citicoline, ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet die Guian ... Provinz Guizhou, 2017 mit dem Angebot von Anreize schaffenden Strategien ... einer eingebetteten Hightech-Schlüsselindustrie. Foto - http://mma.prnewswire.com/media/471342/First_CRH__CHina_Railway_High_Speed__Train_Enters_Guian.jpg ... ... ...
(Date:2/23/2017)... February 23, 2017 Obese people ... caseload for varicose veins in their body. The rising ... prompting the adoption of endovenous laser therapy for treatment ... endovenous laser therapy market, published by Future Market ... choices and consequences of obesity have collectively factored the ...
(Date:2/23/2017)... 23, 2017  As National Nutrition Month approaches, ... Company is helping people live healthier lives by ... savings programs in all 50 states including:  Texas ...  and  California Prescription Assistance Program . ... University for nutritious eating habits: ...
Breaking Medicine Technology: